James Di Santo and Darragh Duffy (MI co-coordinator) – have been funded by the French National Research Agency (ANR) to study variability in the SARS-COV-2 immune response. The project entitled “Systemic and mucosal immune response variation during SARS-CoV-2 infection and recovery” (CoVarImm) will work on one of the 4 priority areas identified by the World Health Organisation to combat COVID19.
As a response to the COVID19 crisis, the ANR launched the Flash ANR COVID19 call to mobilize scientific communities, expedite information on this novel and deadly coronavirus and mount a rapid and efficient response. This call was aimed at examining ideas, actions, innovations in all areas and thus have an accelerated impact on the situation. The immune response to SARS-CoV-2 is the primary cause of the lung pathology and associated morbidities leading to death in a substantial proportion of infected individuals, but this response is highly variable. There is limited knowledge of the kinetics, intensity and diversity of cellular and humoral immune responses following SARS-CoV-2 infection. Using the Milieu Intérieur cohort approach, the CoVarImm study will characterise systemic as well as local nasal mucosal innate and adaptive immune responses during and after SARS-CoV-2 infection. This will facilitate the identification of immune signatures and potential environmental and/or host factors that can distinguish clinical outcomes in COVID-19 patients. The CoVarImm project has the potential to impact on several key clinical decision making choices in the management of COVID-19 patients.
They aim to work together with the scientific community and will share results and data as soon as they are available and contribute towards combating COVID19.